clobazam Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 682 22316-47-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clobazam
  • clobazepam
  • frisium
  • frizium
  • urbadan
A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
  • Molecular weight: 300.74
  • Formula: C16H13ClN2O2
  • CLOGP: 2.44
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 40.62
  • ALOGS: -3.26
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
20 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.19 mg/mL Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 90 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 21, 2011 FDA LUNDBECK LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 1525.27 18.42 754 15513 128755 53204044
Status epilepticus 639.38 18.42 221 16046 14963 53317836
Epilepsy 631.65 18.42 252 16015 25515 53307284
Drug withdrawal convulsions 399.46 18.42 91 16176 1281 53331518
Psychogenic seizure 341.94 18.42 84 16183 1661 53331138
Multiple-drug resistance 272.84 18.42 80 16187 3155 53329644
Somnolence 236.89 18.42 273 15994 167461 53165338
Exposure during pregnancy 201.49 18.42 218 16049 124642 53208157
Drug interaction 200.90 18.42 288 15979 219041 53113758
Abortion spontaneous 192.60 18.42 139 16128 46496 53286303
Partial seizures 179.62 18.42 66 16201 5314 53327485
Generalised tonic-clonic seizure 177.31 18.42 110 16157 28648 53304151
Drug resistance 172.37 18.42 95 16172 19867 53312932
Drug ineffective 147.33 18.42 562 15705 816683 52516116
Paradoxical drug reaction 142.11 18.42 49 16218 3276 53329523
Aggression 132.91 18.42 85 16182 23318 53309481
Foetal exposure during pregnancy 115.56 18.42 91 16176 34624 53298175
Petit mal epilepsy 112.81 18.42 42 16225 3506 53329293
Drug reaction with eosinophilia and systemic symptoms 90.30 18.42 77 16190 32723 53300076
Respiratory disorder neonatal 90.20 18.42 26 16241 963 53331836
Abnormal behaviour 89.79 18.42 65 16202 21801 53310998
Irritability 87.96 18.42 74 16193 30879 53301920
Pain 81.50 18.42 39 16228 588359 52744440
Propofol infusion syndrome 81.49 18.42 23 16244 789 53332010
Mitochondrial DNA mutation 80.37 18.42 18 16249 233 53332566
Rheumatoid arthritis 79.46 18.42 4 16263 314527 53018272
Hyperammonaemia 75.25 18.42 35 16232 5114 53327685
Bradycardia neonatal 74.64 18.42 22 16245 882 53331917
Ataxia 72.62 18.42 49 16218 14688 53318111
Psychomotor skills impaired 68.67 18.42 26 16241 2273 53330526
Selective eating disorder 65.27 18.42 24 16243 1934 53330865
Arthralgia 64.18 18.42 27 16240 439756 52893043
Tonic convulsion 63.90 18.42 21 16246 1210 53331589
Drug level decreased 63.33 18.42 34 16233 6740 53326059
Weight gain poor 63.27 18.42 19 16248 813 53331986
Off label use 60.56 18.42 294 15973 471918 52860881
Nausea 58.42 18.42 88 16179 756003 52576796
Aura 55.56 18.42 18 16249 991 53331808
Gene mutation 55.18 18.42 19 16248 1264 53331535
Premature baby 53.50 18.42 46 16221 19755 53313044
Focal dyscognitive seizures 52.72 18.42 23 16244 2894 53329905
Diarrhoea 52.04 18.42 69 16198 625477 52707322
Seizure cluster 50.70 18.42 12 16255 201 53332598
Atonic seizures 50.64 18.42 15 16252 612 53332187
Drug dependence 50.28 18.42 46 16221 21426 53311373
Disturbance in attention 50.06 18.42 57 16210 34326 53298473
Sedation 49.80 18.42 53 16214 29622 53303177
Anticonvulsant drug level increased 49.54 18.42 18 16249 1402 53331397
Abdominal discomfort 49.52 18.42 5 16262 221057 53111742
Pregnancy 48.99 18.42 54 16213 31387 53301412
Oropharyngeal oedema 48.69 18.42 12 16255 240 53332559
Dyspnoea 48.40 18.42 65 16202 586167 52746632
Lymphangioleiomyomatosis 47.49 18.42 11 16256 167 53332632
Developmental delay 47.16 18.42 17 16250 1294 53331505
Drug level increased 46.36 18.42 43 16224 20378 53312421
Sudden unexplained death in epilepsy 46.34 18.42 12 16255 295 53332504
Low birth weight baby 46.16 18.42 27 16240 6310 53326489
Angiofibroma 46.06 18.42 10 16257 111 53332688
Blood gases abnormal 45.11 18.42 14 16253 670 53332129
Drug hypersensitivity 44.26 18.42 13 16254 265229 53067570
Exposure via breast milk 44.18 18.42 17 16250 1553 53331246
Joint swelling 44.01 18.42 9 16258 234629 53098170
Electroencephalogram abnormal 43.82 18.42 22 16245 3799 53329000
Suicidal behaviour 42.46 18.42 19 16248 2539 53330260
Overdose 42.10 18.42 98 16169 107638 53225161
Systolic dysfunction 41.48 18.42 16 16251 1471 53331328
Maternal exposure during pregnancy 40.82 18.42 122 16145 155517 53177282
Angiomyolipoma 40.82 18.42 10 16257 195 53332604
Hypotonia 39.97 18.42 28 16239 8913 53323886
Hyperammonaemic encephalopathy 39.78 18.42 17 16250 2034 53330765
Depressed mood 38.83 18.42 52 16215 36912 53295887
Gingival hypertrophy 37.71 18.42 15 16252 1496 53331303
Fanconi syndrome 37.39 18.42 14 16253 1186 53331613
Intentional product misuse 36.68 18.42 59 16208 49333 53283466
Psychotic disorder 36.47 18.42 41 16226 24344 53308455
Drop attacks 35.74 18.42 12 16255 739 53332060
Unmasking of previously unidentified disease 34.49 18.42 12 16255 823 53331976
Temporal lobe epilepsy 34.32 18.42 10 16257 385 53332414
Cholestasis of pregnancy 33.69 18.42 13 16254 1196 53331603
Behaviour disorder 33.47 18.42 16 16251 2484 53330315
Coma blister 33.10 18.42 8 16259 147 53332652
Mood altered 32.97 18.42 30 16237 13871 53318928
Infantile spasms 32.91 18.42 9 16258 274 53332525
Myoclonus 31.61 18.42 31 16236 15733 53317066
Cognitive disorder 31.24 18.42 52 16215 44726 53288073
Hepatocellular injury 31.21 18.42 42 16225 29944 53302855
Epileptic psychosis 30.63 18.42 6 16261 38 53332761
Contraindicated product administered 30.53 18.42 3 16264 135626 53197173
Congenital central nervous system anomaly 30.27 18.42 9 16258 372 53332427
Anticonvulsant drug level decreased 29.87 18.42 12 16255 1228 53331571
Brown tumour 29.87 18.42 6 16261 44 53332755
Infusion related reaction 29.19 18.42 6 16261 155951 53176848
Electrocardiogram repolarisation abnormality 29.02 18.42 12 16255 1322 53331477
Hypersomnia 28.84 18.42 30 16237 16325 53316474
Encephalopathy 28.75 18.42 45 16222 36763 53296036
Pain in extremity 28.46 18.42 27 16240 285023 53047776
Drooling 28.36 18.42 16 16251 3492 53329307
Myoclonic epilepsy 28.04 18.42 11 16256 1058 53331741
Balance disorder 27.93 18.42 66 16201 73141 53259658
Hypopnoea 27.55 18.42 14 16253 2479 53330320
Swelling 27.38 18.42 12 16255 191093 53141706
Coma 27.24 18.42 59 16208 61724 53271075
Apnoea 27.00 18.42 21 16246 7832 53324967
Hypothermia 26.79 18.42 26 16241 13030 53319769
Sinusitis 26.77 18.42 9 16258 168555 53164244
Benzodiazepine drug level increased 26.62 18.42 7 16260 183 53332616
Neurosurgery 26.53 18.42 5 16262 25 53332774
Condition aggravated 26.53 18.42 168 16099 296966 53035833
Peripheral swelling 26.43 18.42 15 16252 206093 53126706
Pregnancy on contraceptive 26.38 18.42 11 16256 1238 53331561
Developmental regression 26.37 18.42 5 16262 26 53332773
Therapeutic product effective for unapproved indication 26.22 18.42 6 16261 86 53332713
High-pitched crying 26.21 18.42 5 16262 27 53332772
Herpangina 26.05 18.42 5 16262 28 53332771
Therapeutic product ineffective for unapproved indication 25.93 18.42 7 16260 203 53332596
Polychromasia 25.85 18.42 6 16261 92 53332707
Hallucination, visual 25.36 18.42 30 16237 18802 53313997
Ventricular septal defect 25.18 18.42 16 16251 4334 53328465
Macroglossia 25.09 18.42 9 16258 675 53332124
Congenital tracheomalacia 24.97 18.42 5 16262 36 53332763
Stevens-Johnson syndrome 24.93 18.42 34 16233 24548 53308251
Premature delivery 24.82 18.42 35 16232 26069 53306730
Drug ineffective for unapproved indication 24.65 18.42 31 16236 20689 53312110
Electrocardiogram ST segment elevation 24.62 18.42 15 16252 3774 53329025
Pneumonia aspiration 24.14 18.42 40 16227 34261 53298538
Brain operation 24.03 18.42 8 16259 480 53332319
Cerebral atrophy 23.13 18.42 16 16251 4988 53327811
Poisoning deliberate 23.04 18.42 20 16247 8693 53324106
Diplopia 23.02 18.42 30 16237 20735 53312064
Intentional overdose 22.88 18.42 58 16209 67147 53265652
Speech disorder 22.78 18.42 42 16225 39139 53293660
Excessive eye blinking 22.70 18.42 9 16258 890 53331909
Cough 22.65 18.42 27 16240 256866 53075933
Abdominal pain 22.46 18.42 27 16240 255876 53076923
Ammonia increased 22.03 18.42 15 16252 4558 53328241
Depressed level of consciousness 21.77 18.42 50 16217 54378 53278421
Hypoglycaemia neonatal 21.59 18.42 9 16258 1012 53331787
Stillbirth 20.86 18.42 17 16250 6780 53326019
Intellectual disability 20.48 18.42 8 16259 761 53332038
Nystagmus 20.45 18.42 16 16251 6020 53326779
Dysmorphism 20.21 18.42 11 16256 2239 53330560
Foetal growth restriction 20.05 18.42 17 16250 7157 53325642
Acute pulmonary oedema 19.94 18.42 18 16249 8237 53324562
Change in seizure presentation 19.71 18.42 6 16261 269 53332530
Glioblastoma multiforme 19.47 18.42 8 16259 868 53331931
Fatigue 19.39 18.42 137 16130 730369 52602430
Obsessive thoughts 19.38 18.42 7 16260 536 53332263
Renal failure 19.38 18.42 6 16261 118446 53214353
Blood creatine phosphokinase increased 19.33 18.42 33 16234 28952 53303847
Aphasia 19.17 18.42 34 16233 30744 53302055
Chest pain 18.98 18.42 18 16249 190167 53142632
Calcinosis 18.94 18.42 10 16257 1916 53330883
Live birth 18.66 18.42 23 16244 15036 53317763
Monocyte count decreased 18.65 18.42 10 16257 1976 53330823
Asphyxia 18.61 18.42 15 16252 5886 53326913
Eye movement disorder 18.56 18.42 14 16253 4991 53327808
Hypertension 18.51 18.42 25 16242 225406 53107393
Respiratory syncytial virus bronchiolitis 18.49 18.42 6 16261 332 53332467

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 1366.97 18.93 739 13845 103115 32395827
Status epilepticus 511.54 18.93 195 14389 11811 32487131
Epilepsy 379.10 18.93 189 14395 21920 32477022
Somnolence 319.05 18.93 306 14278 103491 32395451
Drug withdrawal convulsions 277.94 18.93 71 14513 1102 32497840
Generalised tonic-clonic seizure 186.91 18.93 116 14468 20523 32478419
Drug ineffective 180.64 18.93 473 14111 383004 32115938
Multiple-drug resistance 163.05 18.93 62 14522 3713 32495229
Foetal exposure during pregnancy 150.13 18.93 134 14450 41167 32457775
Aggression 141.58 18.93 127 14457 39262 32459680
Partial seizures 123.10 18.93 52 14532 4098 32494844
Petit mal epilepsy 119.21 18.93 46 14538 2866 32496076
Sudden unexplained death in epilepsy 113.91 18.93 29 14555 443 32498499
Abnormal behaviour 106.43 18.93 91 14493 26375 32472567
Drug resistance 102.77 18.93 84 14500 22881 32476061
Drug reaction with eosinophilia and systemic symptoms 92.31 18.93 92 14492 32393 32466549
Sedation 91.91 18.93 72 14512 18454 32480488
Cognitive disorder 90.05 18.93 82 14502 25812 32473130
Respiratory depression 89.60 18.93 62 14522 13149 32485793
Atonic seizures 88.95 18.93 20 14564 173 32498769
Victim of child abuse 86.29 18.93 26 14558 757 32498185
Developmental delay 84.90 18.93 35 14549 2593 32496349
Hypotonia 81.92 18.93 48 14536 7639 32491303
Encephalopathy 81.12 18.93 88 14496 34169 32464773
Ataxia 79.90 18.93 57 14527 12684 32486258
Behaviour disorder 77.18 18.93 36 14548 3588 32495354
Anticonvulsant drug level increased 76.41 18.93 28 14556 1510 32497432
Psychogenic seizure 76.23 18.93 20 14564 346 32498596
Dysmorphism 69.75 18.93 31 14553 2762 32496180
Nystagmus 68.58 18.93 36 14548 4626 32494316
Hamartoma 68.27 18.93 13 14571 43 32498899
Postictal psychosis 66.79 18.93 15 14569 129 32498813
Motor developmental delay 64.14 18.93 19 14565 521 32498421
Dyspnoea 64.10 18.93 42 14542 362003 32136939
Autism spectrum disorder 63.98 18.93 26 14558 1856 32497086
Drug dependence 63.92 18.93 65 14519 23419 32475523
Hyperammonaemic encephalopathy 58.26 18.93 25 14559 2046 32496896
Intellectual disability 57.14 18.93 21 14563 1142 32497800
Cerebral artery thrombosis 56.65 18.93 18 14566 627 32498315
Language disorder 56.44 18.93 24 14560 1921 32497021
Psychomotor retardation 55.73 18.93 27 14557 2928 32496014
Hypospadias 55.37 18.93 27 14557 2970 32495972
Salivary hypersecretion 54.93 18.93 38 14546 8050 32490892
Focal dyscognitive seizures 54.23 18.93 21 14563 1320 32497622
Brain scan abnormal 53.89 18.93 18 14566 736 32498206
Psychomotor skills impaired 53.72 18.93 25 14559 2478 32496464
Anticonvulsant drug level above therapeutic 52.11 18.93 16 14568 497 32498445
Fanconi syndrome 51.30 18.93 22 14562 1798 32497144
Drug interaction 50.19 18.93 212 14372 217973 32280969
Disturbance in attention 49.32 18.93 57 14527 23696 32475246
Depressed level of consciousness 49.14 18.93 75 14509 40772 32458170
Foetal anticonvulsant syndrome 48.04 18.93 18 14566 1033 32497909
Acute kidney injury 47.99 18.93 37 14547 293431 32205511
Hyperammonaemia 47.63 18.93 31 14553 5938 32493004
Pneumonia aspiration 44.55 18.93 72 14512 41084 32457858
Gaze palsy 43.54 18.93 18 14566 1342 32497600
Diarrhoea 42.81 18.93 61 14523 364741 32134201
Product use issue 42.43 18.93 81 14503 52696 32446246
Speech disorder developmental 42.30 18.93 19 14565 1735 32497207
Tonic convulsion 42.12 18.93 16 14568 954 32497988
Irritability 41.17 18.93 53 14531 24601 32474341
Atrial septal defect 40.78 18.93 30 14554 6995 32491947
Cerebellar atrophy 40.48 18.93 13 14571 469 32498473
Developmental regression 40.43 18.93 8 14576 34 32498908
Learning disorder 40.37 18.93 15 14569 841 32498101
Febrile neutropenia 39.33 18.93 4 14580 119562 32379380
Areflexia 38.89 18.93 21 14563 2855 32496087
Chest pain 38.72 18.93 5 14579 124132 32374810
Myoclonic epilepsy 38.43 18.93 15 14569 963 32497979
Death 38.28 18.93 71 14513 382446 32116496
Drop attacks 37.90 18.93 13 14571 577 32498365
Infantile spasms 37.12 18.93 11 14573 302 32498640
Product prescribing error 37.10 18.93 45 14539 19672 32479270
Epidural lipomatosis 36.53 18.93 13 14571 644 32498298
Psychomotor hyperactivity 36.14 18.93 31 14553 9008 32489934
Child abuse 35.63 18.93 11 14573 348 32498594
Anaemia 35.50 18.93 29 14555 223595 32275347
Intensive care unit acquired weakness 35.28 18.93 14 14570 939 32498003
Hypertelorism 34.95 18.93 12 14572 534 32498408
Myocardial infarction 34.85 18.93 7 14577 125669 32373273
Condition aggravated 34.75 18.93 150 14434 155511 32343431
Ehlers-Danlos syndrome 34.45 18.93 7 14577 35 32498907
Benzodiazepine drug level decreased 34.45 18.93 7 14577 35 32498907
Haemophagocytic lymphohistiocytosis 33.83 18.93 33 14551 11302 32487640
Excessive eye blinking 33.36 18.93 11 14573 432 32498510
Pain 32.75 18.93 22 14562 187534 32311408
Neonatal respiratory depression 32.74 18.93 11 14573 458 32498484
Nausea 32.56 18.93 59 14525 320790 32178152
Stevens-Johnson syndrome 32.47 18.93 41 14543 18668 32480274
Hypotonia neonatal 32.29 18.93 14 14570 1175 32497767
Renal tubular acidosis 30.76 18.93 16 14568 2016 32496926
Therapeutic product effect incomplete 30.24 18.93 61 14523 41280 32457662
Electroencephalogram abnormal 29.87 18.93 17 14567 2559 32496383
Hepatocellular injury 29.75 18.93 46 14538 25272 32473670
Circadian rhythm sleep disorder 28.93 18.93 10 14574 454 32498488
Maternal exposure during pregnancy 28.48 18.93 20 14564 4337 32494605
Hyperchloraemia 28.46 18.93 10 14574 477 32498465
Arthralgia 27.86 18.93 16 14568 148432 32350510
Psychotic disorder 27.29 18.93 42 14542 22978 32475964
Product substitution issue 26.78 18.93 28 14556 10408 32488534
Seizure cluster 26.74 18.93 7 14577 120 32498822
Hypernatraemia 26.52 18.93 25 14559 8208 32490734
Retrognathia 26.45 18.93 8 14576 236 32498706
Intentional product misuse 26.13 18.93 53 14531 35998 32462944
Partial seizures with secondary generalisation 26.10 18.93 8 14576 247 32498695
Juvenile idiopathic arthritis 26.03 18.93 13 14571 1505 32497437
Product administered to patient of inappropriate age 25.95 18.93 16 14568 2790 32496152
Change in seizure presentation 25.81 18.93 6 14578 61 32498881
Drug level increased 25.74 18.93 38 14546 20042 32478900
Hypothermia 25.74 18.93 27 14557 10076 32488866
Dysgraphia 25.68 18.93 14 14570 1939 32497003
Cardiac failure 25.63 18.93 5 14579 91668 32407274
Developmental coordination disorder 25.31 18.93 7 14577 149 32498793
Haemoglobin decreased 25.31 18.93 11 14573 119660 32379282
Irregular sleep phase 25.14 18.93 6 14578 69 32498873
Pain in extremity 25.03 18.93 11 14573 118890 32380052
Cerebellar syndrome 24.33 18.93 14 14570 2152 32496790
Body dysmorphic disorder 23.13 18.93 6 14578 99 32498843
Agitation 23.00 18.93 67 14517 57169 32441773
Bronchiolitis 22.92 18.93 15 14569 2898 32496044
Fatigue 22.75 18.93 81 14503 350620 32148322
Ear infection 22.28 18.93 23 14561 8425 32490517
Respiratory distress 22.28 18.93 49 14535 35197 32463745
Myoclonus 22.18 18.93 30 14554 14599 32484343
Fine motor delay 22.13 18.93 7 14577 240 32498702
Clinodactyly 21.73 18.93 7 14577 255 32498687
Low set ears 21.71 18.93 8 14576 438 32498504
Reaction to excipient 21.64 18.93 8 14576 442 32498500
Atrial fibrillation 21.29 18.93 13 14571 116691 32382251
Dystonia 21.22 18.93 25 14559 10598 32488344
Educational problem 21.14 18.93 8 14576 472 32498470
Otitis media acute 20.92 18.93 8 14576 486 32498456
Back pain 20.78 18.93 12 14572 111041 32387901
Extrapyramidal disorder 20.53 18.93 26 14558 11869 32487073
Anger 20.51 18.93 26 14558 11878 32487064
Limb malformation 20.46 18.93 8 14576 516 32498426
Oedema peripheral 20.41 18.93 13 14571 114078 32384864
Off label use 20.25 18.93 218 14366 306102 32192840
Coma 20.21 18.93 53 14531 42559 32456383
Logorrhoea 20.16 18.93 13 14571 2449 32496493
Withdrawal syndrome 20.14 18.93 26 14558 12096 32486846
Dyskinesia 19.91 18.93 37 14547 23566 32475376
Pelvic deformity 19.85 18.93 4 14580 19 32498923
Wrist deformity 19.68 18.93 7 14577 346 32498596
Haematuria traumatic 19.46 18.93 6 14578 189 32498753
Blood glucose increased 19.45 18.93 3 14581 65238 32433704
Muscle contracture 19.16 18.93 10 14574 1269 32497673
Patent ductus arteriosus 19.00 18.93 14 14570 3271 32495671
Floppy infant 18.97 18.93 5 14579 88 32498854
Drooling 18.95 18.93 14 14570 3283 32495659
Blood pressure increased 18.94 18.93 6 14578 79348 32419594

Pharmacologic Action:

SourceCodeDescription
ATC N05BA09 NERVOUS SYSTEM
PSYCHOLEPTICS
ANXIOLYTICS
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
MeSH PA D018755 GABA Agonists
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D058785 GABA-A Receptor Agonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175694 Benzodiazepine
FDA MoA N0000182137 Cytochrome P450 2D6 Inhibitors
FDA MoA N0000185506 Cytochrome P450 3A4 Inducers
CHEBI has role CHEBI:35474 minor tranquilisers
CHEBI has role CHEBI:35623 antiepileptic
CHEBI has role CHEBI:50268 GABA modulators

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Lennox-Gastaut syndrome indication 230418006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.14 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL

External reference:

IDSource
4025788 VUID
N0000179086 NUI
D01253 KEGG_DRUG
C0055891 UMLSCUI
CHEBI:31413 CHEBI
CHEMBL70418 ChEMBL_ID
DB00349 DRUGBANK_ID
D000078306 MESH_DESCRIPTOR_UI
2789 PUBCHEM_CID
7149 IUPHAR_LIGAND_ID
3055 INN_ID
2MRO291B4U UNII
151794 RXNORM
14923 MMSL
66309 MMSL
d04557 MMSL
003693 NDDF
387572002 SNOMEDCT_US
96236000 SNOMEDCT_US
4025788 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0054-0526 TABLET 10 mg ORAL ANDA 31 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0054-0527 TABLET 20 mg ORAL ANDA 31 sections
clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0054-0561 SOLUTION 2.50 mg ORAL ANDA 32 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0378-8043 SUSPENSION 2.50 mg ORAL ANDA 35 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0527-1681 TABLET 10 mg ORAL ANDA 32 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0527-1682 TABLET 20 mg ORAL ANDA 32 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0527-5301 SUSPENSION 2.50 mg ORAL ANDA 33 sections
Clobazam Human Prescription Drug Label 1 0781-8013 TABLET 10 mg ORAL ANDA 32 sections
Clobazam Human Prescription Drug Label 1 0781-8014 TABLET 20 mg ORAL ANDA 32 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0832-0580 TABLET 10 mg ORAL ANDA 39 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0832-0581 TABLET 20 mg ORAL ANDA 39 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 0832-0585 SUSPENSION 2.50 mg ORAL ANDA 40 sections
SYMPAZAN HUMAN PRESCRIPTION DRUG LABEL 1 10094-205 FILM 5 mg ORAL NDA 36 sections
SYMPAZAN HUMAN PRESCRIPTION DRUG LABEL 1 10094-210 FILM 10 mg ORAL NDA 36 sections
SYMPAZAN HUMAN PRESCRIPTION DRUG LABEL 1 10094-220 FILM 20 mg ORAL NDA 36 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 16714-087 SUSPENSION 2.50 mg ORAL ANDA 34 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 16714-887 TABLET 10 mg ORAL ANDA 32 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 16714-888 TABLET 20 mg ORAL ANDA 32 sections
CLOBAZAM HUMAN PRESCRIPTION DRUG LABEL 1 16729-445 TABLET 10 mg ORAL ANDA 32 sections
CLOBAZAM HUMAN PRESCRIPTION DRUG LABEL 1 16729-446 TABLET 20 mg ORAL ANDA 32 sections
Clobazam Human Prescription Drug Label 1 31722-639 TABLET 10 mg ORAL ANDA 31 sections
Clobazam Human Prescription Drug Label 1 31722-640 TABLET 20 mg ORAL ANDA 31 sections
Clobazam Human Prescription Drug Label 1 31722-641 SUSPENSION 2.50 mg ORAL ANDA 34 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 42571-315 TABLET 10 mg ORAL ANDA 33 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 42571-316 TABLET 20 mg ORAL ANDA 33 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51672-4202 TABLET 10 mg ORAL ANDA 33 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51672-4203 TABLET 20 mg ORAL ANDA 33 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51672-4210 SUSPENSION 2.50 mg ORAL ANDA 35 sections
Clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51672-4227 SUSPENSION 2.50 mg ORAL ANDA 40 sections
clobazam HUMAN PRESCRIPTION DRUG LABEL 1 51991-900 TABLET 10 mg ORAL ANDA 39 sections